MX9707278A - Derivados tipo mercapto y seleno como inhibidores de la oxido nitrico sintasa. - Google Patents

Derivados tipo mercapto y seleno como inhibidores de la oxido nitrico sintasa.

Info

Publication number
MX9707278A
MX9707278A MX9707278A MX9707278A MX9707278A MX 9707278 A MX9707278 A MX 9707278A MX 9707278 A MX9707278 A MX 9707278A MX 9707278 A MX9707278 A MX 9707278A MX 9707278 A MX9707278 A MX 9707278A
Authority
MX
Mexico
Prior art keywords
nitric oxide
oxide synthase
mercapto
inhibitors
inhibiting
Prior art date
Application number
MX9707278A
Other languages
English (en)
Inventor
Garry J Southan
Andrew L Salzman
Csaba Szabo
Original Assignee
Childrens Hosp Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/410,312 external-priority patent/US5674907A/en
Application filed by Childrens Hosp Medical Center filed Critical Childrens Hosp Medical Center
Publication of MX9707278A publication Critical patent/MX9707278A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Esta invencion de dirige a una composicion farmacologicamente aceptable para inhibir la oxido nítrico sintasa en un mamífero, que incluye un derivado tipo mercapto o seleno y un vehículo farmacéuticamente aceptable. La invencion también concierna a un método de inhibir la oxido nítrico sintasa, inhibiendo selectivamente la isoforma inducible de la oxido nítrico sintasa y tratando diversas condiciones en donde existe una ventaja al inhibir la biosíntesis de oxido nítrico. EL método incluye la etapa de administrar a un mamífero un derivado tipo mercapto o seleno en forma pura o en un vehículo farmacéuticamente aceptables.
MX9707278A 1995-03-24 1997-09-24 Derivados tipo mercapto y seleno como inhibidores de la oxido nitrico sintasa. MX9707278A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/410,312 US5674907A (en) 1995-03-24 1995-03-24 Mercapto derivatives as inhibitors of nitric oxide synthase
US08/545,952 US5929063A (en) 1995-03-24 1995-10-20 Mercapto and seleno derivatives as inhibitors of nitric oxide synthase

Publications (1)

Publication Number Publication Date
MX9707278A true MX9707278A (es) 1998-06-30

Family

ID=27020952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9707278A MX9707278A (es) 1995-03-24 1997-09-24 Derivados tipo mercapto y seleno como inhibidores de la oxido nitrico sintasa.

Country Status (17)

Country Link
US (2) US5929063A (es)
EP (1) EP0814792B1 (es)
JP (1) JPH11502847A (es)
CN (1) CN1275594C (es)
AT (1) ATE241347T1 (es)
AU (1) AU695307B2 (es)
BR (1) BR9607951A (es)
CA (1) CA2214601C (es)
CZ (1) CZ293497A3 (es)
DE (1) DE69628416T2 (es)
DK (1) DK0814792T3 (es)
HU (1) HUP9801698A3 (es)
MX (1) MX9707278A (es)
NZ (1) NZ305228A (es)
RU (1) RU2191575C2 (es)
TR (1) TR199701013T1 (es)
WO (1) WO1996030007A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199801731T2 (xx) * 1996-03-05 1999-02-22 Children's Hospital Medical Center Siklooksijenaz önleyicileri olarak merkapto türevleri.
AU3128197A (en) * 1996-05-30 1998-01-05 Children's Hospital Medical Center Guanidino derivatives as inhibitors of the cytotoxic effect of peroxynitrite
ATE448782T1 (de) 1996-12-31 2009-12-15 Antioxidant Pharmaceuticals Co Pharmazeutische glutathionpräparate und methoden zu dern verabreichung
FR2782642B1 (fr) * 1998-08-31 2001-12-07 Xavier Forceville Utilisation du selenium pour le traitement de patients atteints d'un syndrome de reponse inflammatoire systemique (sirs), et composition pour la mise en oeuvre du traitement
PL346860A1 (en) 1998-09-08 2002-03-11 Monsanto Co Methods of treating osteoarthritis with inducible nitric oxide synthase inhibitors
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
DE102004063638A1 (de) * 2004-12-31 2006-07-13 Biosyn Arzneimittel Gmbh Selen-haltige Medikamente zur Prophylaxe oder Therapie von endothelialen Gefäßerkrankungen
EP1931328A4 (en) * 2005-08-16 2011-07-13 Discogen Llc METHOD FOR TREATING A GREENER SUBJECT WITH DEGENERATIVE DISCOPATHY USING AN INHIBITOR OF NITRIC OXIDE SYNTHASE
TW200744658A (en) * 2005-10-12 2007-12-16 Pentapharm Ag Topical composition for use as a skin lightener
US20080306148A1 (en) * 2007-04-13 2008-12-11 The Penn State Research Foundation Anti-cancer compositions and methods
US8003633B1 (en) 2008-04-14 2011-08-23 The Penn State Research Foundation Anti-cancer compositions and methods
CN114057619B (zh) * 2020-07-31 2024-03-22 深圳福山生物科技有限公司 有机硒化合物及其治疗用途
CN115785573B (zh) * 2022-12-02 2024-05-17 福建奥翔体育塑胶科技股份有限公司 一种持久抗菌型epdm颗粒及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1400319A (en) * 1972-04-20 1975-07-16 Smith Kline French Lab Pharmaceutical compositions
EP0547558B1 (en) * 1991-12-16 2000-04-19 Washington University Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation
US5246971A (en) * 1991-12-16 1993-09-21 Washington University Method of inhibiting nitric oxide formation
US5298506A (en) * 1992-05-08 1994-03-29 Brigham And Women's Hospital Use of guanylate cyclase inhibitors in the treatment of shock
AU5533094A (en) * 1992-11-27 1994-06-22 Wellcome Foundation Limited, The Enzyme inhibitors

Also Published As

Publication number Publication date
HUP9801698A2 (hu) 1998-11-30
AU5319196A (en) 1996-10-16
US5929063A (en) 1999-07-27
TR199701013T1 (xx) 1998-02-21
EP0814792B1 (en) 2003-05-28
RU2191575C2 (ru) 2002-10-27
ATE241347T1 (de) 2003-06-15
DE69628416T2 (de) 2004-05-06
NZ305228A (en) 1999-01-28
CZ293497A3 (cs) 1998-02-18
AU695307B2 (en) 1998-08-13
BR9607951A (pt) 1999-06-01
CA2214601C (en) 2001-09-25
DE69628416D1 (de) 2003-07-03
US5985917A (en) 1999-11-16
CA2214601A1 (en) 1996-10-03
EP0814792A1 (en) 1998-01-07
CN1275594C (zh) 2006-09-20
JPH11502847A (ja) 1999-03-09
WO1996030007A1 (en) 1996-10-03
HUP9801698A3 (en) 2000-07-28
DK0814792T3 (da) 2003-09-29
CN1181700A (zh) 1998-05-13

Similar Documents

Publication Publication Date Title
MX9707278A (es) Derivados tipo mercapto y seleno como inhibidores de la oxido nitrico sintasa.
UA49006C2 (uk) Похідні 6-фенілпіридил-2-аміну, фармацевтична композиція, спосіб інгібування синтази оксиду нітрогену у ссавців та спосіб лікування
CA2222303A1 (fr) Utilisation d'au moins un inhibiteur de no-synthase dans le traitement des peaux sensibles
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
NZ334512A (en) Method of using tetracycline compounds for inhibition of nitric oxide production
UA35589C2 (uk) ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
BG102259A (en) Compostions with controlled paroxetine release
IL125285A0 (en) Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and pharmaceutical compositions containing the same
JO1696B1 (en) Acetamide derivatives
MXPA01003501A (es) Metodo para moderar el estres o tension de las plantas.
EP0861238A4 (en) DERIVATIVES OF HEXAHYDRO-5-IMINO-1,4-HETEROAZEPINE INHIBITORS OF NITRIC OXIDE SYNTHASES
EP0727987A4 (en) INHIBITION OF THE BREATHING SALVE USING POSTTRANSLATIONAL MODIFICATION INHIBITORS RELATING TO MODIFICATION
WO2000078296A3 (en) Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
WO2000009120A8 (en) New use of taxoid derivatives
UA29415C2 (uk) Засіб для попередження блювання і фармацевтичний препарат
HK1024164A1 (en) Use of composition and a cosmetic method for reducing or preventing stinging
AP9801261A0 (en) Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer.
MX9707046A (es) Composiciones que comprenden nicotinilalanina y un inhibidor de conjugacion de glicina o vitamina b6.
AU1759901A (en) Compositions and methods for regulating endogenous inhibitor of atp synthase, including treatment for diabetes
TR199801731T2 (xx) Siklooksijenaz önleyicileri olarak merkapto türevleri.
EP0711164A1 (en) 4-AZA-PREGNAN-5-ALPHA REDUCTASE ISOZYM 1 INHIBITORS
ZA974683B (en) Oxime derivatives of fenamates as inhibitors of prostaglandin biosynthesis.
IL124870A0 (en) Nitric oxide (no) synthase inhibitor to treat or prevent type ii diabetes
SG44827A1 (en) Compounds useful as antiproliferative agents and garft inhibitors
ZA982808B (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees